Prosecution Insights
Last updated: August 17, 2026
Application No. 18/399,092

6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER

Non-Final OA §112
Filed
Dec 28, 2023
Priority
Aug 04, 2017 — provisional 62/541,631 +2 more
Examiner
YOO, SUN JAE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Dana-Farber Cancer Institute Inc.
OA Round
4 (Non-Final)
71%
Grant Probability
Favorable
4-5
OA Rounds
1m
Est. Remaining
71%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
876 granted / 1234 resolved
+11.0% vs TC avg
Minimal +0% lift
Without
With
+0.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
111 currently pending
Career history
1296
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
17.0%
-23.0% vs TC avg
§102
27.6%
-12.4% vs TC avg
§112
33.8%
-6.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1234 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on May 4, 2026 has been entered. Claim Objections 3. Claim 8 objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Response to Amendment 4. The amendments to the claims filed on May 4, 2026 have been fully considered. 5. The amendments to the claims filed on May 4, 2026 are sufficient to overcome the 35 USC 103 rejection over RN 36735-37-2 which is withdrawn. The amendments are not sufficient to overcome the 35 USC 102 rejection over RN 21282-90-6 which is maintained. Below are responses to Applicant’s remarks. The claims were previously rejected as being anticipated by RN 21282-90-6. The reference teaches a compound and composition thereof in water which correspond to the present claims in the following manner: R1=R2=R6=R7=H, R3=NR6R7. Applicants have amended claims 2, 3 and 7 such that R7=H is no longer claimed. However, claims 1, 6 and 10-12 include the embodiment of R7=H. Therefore, this rejection is withdrawn for claims 2, 3 and 7 and maintained for claims 1, 6 and 10-12. 6. The claim amendments necessitated a new ground of rejection under 35 USC 112. 7. Claim 8 remains objected to for being dependent on a base rejected claim. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. 8. Claims 1-7 and 9-12 rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The claims have been amended to include the proviso that R3 cannot be morpholiny-4-yl if R1 and R2 are hydrogen. The subgenus delineated by this proviso was not described in the original disclosure. Moreover, the compounds do not sufficiently support this subgenus. For this reason, the proviso adds new matter to the claims. Appropriate correction is required. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUN JAE YOO whose telephone number is (571)272-9074. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUN JAE YOO/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Show 1 earlier event
Mar 20, 2025
Non-Final Rejection mailed — §112
Jun 20, 2025
Response Filed
Jul 28, 2025
Non-Final Rejection mailed — §112
Dec 26, 2025
Response Filed
Feb 02, 2026
Final Rejection mailed — §112
May 04, 2026
Request for Continued Examination
May 05, 2026
Response after Non-Final Action
Jun 24, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12692253
Antimicrobial Compounds and Methods
5y 0m to grant Granted Jul 28, 2026
Patent 12690381
ORGANOMETALLIC COMPOUND AND APPLICATION THEREOF
2y 8m to grant Granted Jul 21, 2026
Patent 12674026
PROCESS FOR PREPARING POLYOL-BASED ESTERS OF ACYL-CAPPED HYDROXY CARBOXYLIC ACIDS
4y 6m to grant Granted Jul 07, 2026
Patent 12661353
SPT5 INHIBITORS AND USES THEREOF
4y 10m to grant Granted Jun 23, 2026
Patent 12662459
METHOD FOR THE SYNTHESIS OF 3-R-1,4,2-DIOXAZOL-5-ONES
2y 2m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
71%
Grant Probability
71%
With Interview (+0.3%)
2y 8m (~1m remaining)
Median Time to Grant
High
PTA Risk
Based on 1234 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month